How much funding has MetaSight Diagnostics raised?

MetaSight Diagnostics has raised $20M in total funding. Their latest funding round was Series A. Key investors include aMoon Velocity, aMoon Growth II Fund, ARC Ventures, Saban Ventures, Alumni Ventures.

Where is MetaSight Diagnostics headquartered?

MetaSight Diagnostics is headquartered in Rehovot, Israel. The company has a team of 11-50 people.

What does MetaSight Diagnostics do?

MetaSight Diagnostics operates in the AI in Healthcare sector. Israeli liquid biopsy diagnostics company developing affordable, mass spectrometry-based multi-omics blood tests for early detection of cancer and chronic diseases Developing affordable and precise liquid biopsy diagnostics for early detection of chronic and acute diseases using proprietary mass spectrometry multi-omics technology (metabolomics, lipidomics, proteomics) at a cost of a few dollars per test

When was MetaSight Diagnostics founded?

MetaSight Diagnostics was founded in 2020. It is based in Rehovot, Israel.

Who is the CEO of MetaSight Diagnostics?

Prof. Tomer Shlomi is the CEO of MetaSight Diagnostics. The company was founded in 2020.

Where is MetaSight Diagnostics located?

MetaSight Diagnostics is headquartered in Rehovot, Israel.

What funding stage is MetaSight Diagnostics at?

MetaSight Diagnostics is currently at the Acquired stage.

How many employees does MetaSight Diagnostics have?

MetaSight Diagnostics has approximately 11-50 employees.

MetaSight Diagnostics

Category: AI in Healthcare

Israeli liquid biopsy diagnostics company developing affordable, mass spectrometry-based multi-omics blood tests for early detection of cancer and chronic diseases MetaSight Diagnostics was founded in 2020. The company is led by Prof. Tomer Shlomi. Based in Rehovot, Israel. Team size: 11-50. Total funding raised: $20M. Latest round: Series A. Key investors include aMoon Velocity, aMoon Growth II Fund, ARC Ventures, Saban Ventures, Alumni Ventures.

Founded: 2020
Headquarters: Rehovot, Israel
Team size: 11-50
Total funding: $20M

Value proposition

Developing affordable and precise liquid biopsy diagnostics for early detection of chronic and acute diseases using proprietary mass spectrometry multi-omics technology (metabolomics, lipidomics, proteomics) at a cost of a few dollars per test

Products and solutions

Liquid biopsy blood tests for early detection of colorectal cancer (CRC), Metabolic dysfunction-associated steatohepatitis (MASH)/liver fibrosis, myocardial infarction, diabetic kidney disease, pancreatic cancer, and lung cancer, Proprietary mass spectrometry-based diagnostics discovery engine, World's largest serum metabolomics dataset linked to longitudinal EHR data

Unique value

Cost-effective ($1/sample with <1 min processing time) mass spectrometry-based multi-omics approach vs. expensive NGS-based liquid biopsies; World's largest metabolomics dataset linked to longitudinal EHRs; Unbiased, comprehensive multi-omics biomarker discovery at population scale

Target customer

Healthcare providers, clinical laboratories, population health programs, HMOs

Industries served

Diagnostics, Oncology, Hepatology, Cardiology, Nephrology, Population Health

Technology advantage

Proprietary high-throughput mass spectrometry technology (metabolomics, lipidomics, proteomics) enabling $1/sample processing; World's largest and most comprehensive serum metabolomics dataset linked to electronic medical records; AI-powered multi-omics biomarker discovery platform; Partnership with Maccabi Health Services (KSM) providing access to hundreds of thousands of de-identified serum samples and EHRs

How they differentiate

Uses mass spectrometry multi-omics (metabolomics, lipidomics, proteomics) rather than NGS-based approaches used by most liquid biopsy companies; Significantly lower cost per test ($1/sample); World's largest metabolomics dataset linked to longitudinal EHRs; Focus on both oncology and non-oncology chronic diseases (liver, cardiovascular, kidney)

Main competitors

Guardant Health (acquirer), Exact Sciences (Cologuard), Grail (Illumina), Freenome, Delfi Diagnostics

Key partnerships

Kahn-Sagol-Maccabi (KSM) Research and Innovation Center of Maccabi Health Services (Israel's leading HMO) — large-scale metabolomics research collaboration, Thermo Fisher Scientific (Vanquish LC and Orbitrap MS technology), aMoon Velocity (incubator/launchpad program)

Notable customers

Maccabi Health Services (Israel's leading HMO, via KSM research partnership)

Major milestones

2020: Founded by Prof. Tomer Shlomi (Technion) in partnership with aMoon Velocity, 2023 (Jul): Emerged from stealth, announced partnership with Maccabi's KSM Research Center, 2024 (Nov): Raised $8M oversubscribed Series A, 2025: Recognized by TheMarker as one of top 20 startups in Israel, 2026 (Feb): Acquired by Guardant Health for up to $150M

Growth metrics

20 employees at time of acquisition (Feb 2026); 25% YoY headcount growth; Raised ~$20M total; Acquired for up to $150M ($59M upfront + $90M milestones)

Market positioning

Acquired by Guardant Health (Nasdaq: GH, ~$14B market cap) for up to $150M; positioned as Guardant's first R&D center outside the US; differentiated mass spectrometry approach complements Guardant's NGS-based Shield platform

Geographic focus

Israel (HQ and R&D); Global market via Guardant Health

About Prof. Tomer Shlomi

Professor of Computer Science & Biology at Technion – Israel Institute of Technology; Head of Cancer Metabolism and Systems Biology Lab at Technion

Latest news about MetaSight Diagnostics

Guardant Health acquired Israeli cancer detection startup MetaSight for up to $150M, establishing its first R&D center outside the US. This move signals rapid consolidation in the $14B liquid biopsy s

More AI in Healthcare companies

Official website: https://metasightdx.com